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Purpose: Stereotactic body radiation therapy (SBRT) is increasingly utilized as primary
treatment for clinically localized prostate cancer. Consensus regarding the appropriate
patient-reported outcome (PRO) endpoints for clinical trials evaluating radiation modalities
for early stage prostate cancer is lacking. To aid in clinical trial design, this study presents
PROs over a 36-month period following SBRT for clinically localized prostate cancer.
Methods: Between February 2008 and September 2010, 174 hormone-naïve patients with
clinically localized prostate cancer were treated with 35–36.25 Gy SBRT (CyberKnife, Accu-
ray) delivered in 5 fractions. Patients completed the validated Expanded Prostate Cancer
Index Composite (EPIC)-26 questionnaire at baseline and all follow-ups. The proportion of
patients developing a clinically significant decline in each EPIC domain score was deter-
mined. The minimally important difference (MID) was defined as a change of one-half the
standard deviation from the baseline. Per RadiationTherapy Oncology Group (RTOG) 0938,
we also examined the patients who experienced a decline in EPIC urinary domain sum-
mary score of >2 points (unacceptable toxicity defined as ≥60% of all patients reporting
this degree of decline) and EPIC bowel domain summary score of>5 points (unacceptable
toxicity defined as >55% of all patients reporting this degree of decline) from baseline to
1 year.
Results: A total of 174 patients at a median age of 69 years received SBRT with a mini-
mum follow-up of 36 months. The proportion of patients reporting a clinically significant
decline (MID for urinary/bowel are 5.5/4.4) in EPIC urinary/bowel domain scores was
34%/30% at 6 months, 40%/32.2% at 12 months, and 32.8%/21.5% at 36 months. The
patients reporting a decrease in the EPIC urinary domain summary score of >2 points
was 43.2% (CI: 33.7%, 54.6%) at 6 months, 51.6% (CI: 43.4%, 59.7%) at 12 months, and
41.8% (CI: 33.3%, 50.6%) at 36 months. The patients reporting a decrease in the EPIC
bowel domain summary score of >5 points was 29.6% (CI: 21.9%, 39.3%) at 6 months,
29% (CI: 22%, 36.8%) at 12 months, and 22.4% (CI: 15.7%, 30.4%) at 36 months.
Conclusion: Following prostate SBRT, clinically significant urinary symptoms are more
common than bowel symptoms. Our prostate SBRT treatment protocol meets the RTOG
0938 criteria for moving forward to a Phase III trial comparing it to conventionally frac-
tionated radiation therapy. Notably, between 12 and 36 months, the proportion of patients
reporting a significant decrease in both EPIC urinary and bowel domain scores declined,
suggesting a late improvement in these symptom domains. Further investigation is needed
to elucidate (1) which EPIC domains bear the greatest influence on post-treatment quality
of life and (2) at what time point PRO endpoint(s) should be assessed.
Keywords: prostate cancer, SBRT, CyberKnife, EPIC, patient-reported outcome, toxicity
Abbreviations: ADT, androgen deprivation therapy; CT, computed tomography;
CTCAE, common terminology criteria for adverse events; CTV, clinical target vol-
ume; DVH, dose–volume histogram; EBRT, external-beam radiation therapy; EPIC,
expanded prostate index composite; GI, gastrointestinal; GTV, gross target volume;
GU, genitourinary; IMRT, intensity-modulated radiation therapy; MID, minimal
important difference; PTV, planning target volume; QOL, quality of life; RTOG,
radiation therapy oncology group; SBRT, stereotactic body radiation therapy; SD,
standard deviation.
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INTRODUCTION
Stereotactic body radiation therapy (SBRT) is a new standard treat-
ment option for clinically localized prostate cancer (1, 2). SBRT
delivers high doses of radiation with precision to the prostate
and adjacent tissues while minimizing radiation exposure to blad-
der and rectum (3, 4). Biochemical disease free survival has been
shown to be high with SBRT (2, 5), demonstrating toxicity com-
parable to conventionally fractionated radiation therapy despite
greater doses per fraction and higher biologically effective doses
(5–8). Presently, evidence supporting superior outcomes associ-
ated with any particular radiation treatment approach for localized
prostate cancer remains limited (9). As a result, the choice of
intervention is guided by the treatment’s toxicity profile and the
patient’s subsequent quality of life (QOL) (10).
Due to the close proximity of the bladder and rectum to the
prostate, urinary and bowel toxicities are unavoidable follow-
ing prostate cancer radiotherapy. These toxicities are commonly
employed as the co-primary endpoints for Phase II trials eval-
uating the suitability of a new treatment option for clinically
localized prostate cancer (11, 12). The clinical significance of
these toxicities is determined by their severity, duration, and
associated bother. Toxicity grade is clinician-assessed utilizing
the items from the National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events (CTCAE). The incidence
of late genitourinary (GU) and gastrointestinal (GI) toxicity (≥
grade 2) after external-beam radiation therapy ranges from 10 to
30%, generally occurring within the first 3 years. Recent data sug-
gest that many low grade toxicities may resolve with time, and
analysis of actuarial incidence may over-estimate their clinical
significance (13).
Physicians’ assessment of treatment-associated toxicities is his-
torically unreliable (14), and in fact may underestimate their
severity (15, 16). Compared with physician-reported data, patient
responses to validated questionnaires may better illustrate longitu-
dinal trends in toxicity following radiotherapy (17). The Expanded
Prostate Cancer Index Composite (EPIC)-26, a validated patient-
reported outcome (PRO) instrument that evaluates health-related
QOL, has been utilized to compare prostate cancer treatments with
similar efficacy but differing toxicity profiles (10, 18, 19). Increas-
ingly, PRO are integrated into clinical trial design (20), though
interpretation of missing data (21, 22) and the selection of appro-
priate outcome measures complicate the meaningful use of PROs
in the trial setting.
A key to utilizing PRO in clinical trials is determining thresholds
for minimal important difference (MID) (23–25). An MID is the
smallest difference in a questionnaire domain score, which patients
perceive as a meaningful change (26). The MID for a given domain
is important in determining the required number of patients for
study recruitment and interpreting the questionnaire results. It
varies depending on the specific domain questionnaire utilized
and the demographics of the patient population being studied.
The MID may be determined statistically or by comparison to
results with a standard treatment (27). The most commonly used
statistical approach is to utilize one-half SD of the baseline domain
score (23), which is specific to the patient population being ana-
lyzed. Such a distribution approach has been criticized because
it does not provide information on the clinical relevance of the
observed change (26). In general, most approaches lead to MIDs
that are 5–10% of the instrument range (23–25, 28).
What PRO endpoint should be utilized to determine if the
toxicity profile of a new treatment is associated with a supe-
rior QOL? Radiation Therapy Oncology Group (RTOG) 0938
(http://www.rtog.org), a phase II trial comparing different SBRT
hypofractionation regiments, compares urinary and bowel QOL
1 year following SBRT to that following conventionally fraction-
ated external-beam radiation therapy (standard arm from RTOG
0415; 73.8 Gy in 41 fractions). In the opinion of the investigators,
the percentage of patients with change in EPIC bowel domain
score (baseline to 1-year) that was worse than five points and a
change in EPIC urinary domain score (baseline to 1-year) that
was worse than two points are felt to be clinically meaningful end-
points to assess for tolerability and safety. One year was chosen as
a balance between a sufficient time to assess late toxicity with still
adequate number of patients following up to minimize the impact
of missing data.
To date, limited data are available on PROs following SBRT to
aid in clinical trial design. The objective of this study is to report
the urinary and bowel QOL outcomes following SBRT in patients
with clinically localized prostate cancer. These PROs may in turn
help inform selection of appropriate endpoints in the design of
future clinical trials.
MATERIALS AND METHODS
PATIENT SELECTION
Eligible patients had a diagnosis of prostate cancer and were
treated per our institutional protocol. Risk category was defined
using the D’Amico classification (9). Patients who received andro-
gen deprivation therapy (ADT) were excluded from this study
due to its known adverse effects on PROs (29). Institutional IRB
approval was obtained for retrospective review of data that were
prospectively collected in our institutional database.
SBRT TREATMENT PLANNING AND DELIVERY
Stereotactic body radiation therapy treatment planning and deliv-
ery were performed as previously described (4, 7). Gold fiducial
markers were placed into the prostate using ultrasound guid-
ance. Treatment plans were created using fused thin cut computed
tomography (CT) images and high-resolution magnetic reso-
nance (MR) images. The clinical target volume (CTV) included
the prostate and proximal seminal vesicles. The planning target
volume (PTV) included a 5 mm anterolateral expansion and a
3 mm posterior expansion around the CTV. A prescription dose
of 35–36.25 Gy was delivered to the PTV in five fractions of 7–
7.25 Gy over 1–2 weeks. The prescription isodose line was limited
to ≥75%. The bladder, membranous urethra, and rectum were
contoured and evaluated with dose–volume histogram analysis
during treatment planning. Target position was confirmed multi-
ple times during each treatment with a minimum of three properly
placed fiducials (4).
FOLLOW-UP AND STATISTICAL ANALYSIS
Patients completed the EPIC-26 (30) before treatment and during
routine follow-up visits 1 month after the completion of SBRT,
every 3 months for the first year, and then every 6 months for the
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second and third years. To minimize the impact of missing data,
patients who missed follow-ups were contacted and asked to fill out
the questionnaires. The EPIC-26 is a validated tool that measures
urinary and bowel QOL (30). To statistically compare changes
between two time points, the levels of responses were assigned a
score and the significance of the mean changes in the scores was
assessed by paired t -test. Responses to the EPIC-26 questionnaire
were grouped by physiological domains and assigned numerical
scores. The multi-item scale scores were transformed linearly to
a 0–100 scale as recommended in the scoring instructions for
the EPIC-26. Lower numbers corresponded to worsening func-
tion and increased bother. Wilcoxon Signed-Rank Test analysis
was used to assess differences in QOL scores compared to base-
line. Paired t -test was used to assess significance of the change
in scores. The MID to assess for clinically significant change in
HRQOL from baseline was set as half an SD (23). Per RTOG
0938, we also examined the percentage of patients who experi-
enced a decline in EPIC urinary domain summary score of >2
points (unacceptable toxicity defined as ≥60% of all patients
reporting this degree of decline) and EPIC bowel domain sum-
mary score of >5 points (unacceptable toxicity defined as >55%
of all patients reporting this degree of decline) from baseline to
1 year.
RESULTS
From February 2008 to September 2010, 174 hormone-naïve
patients with clinically localized prostate adenocarcinoma were
treated per our institutional SBRT monotherapy protocol. The
patients were followed for a minimum of 36 months following
SBRT (range: 37–69 months). The median patient age was 69 (48–
90) years (Table 1). 55.7% of patients self-identified as white and
39.1% as black. Forty-two percent of patients were D’Amico low
risk, 52.9% of patients were intermediate risk, and 5.1% of patients
were high risk. The median prostate volume was 37.3 (11.6–138.7)
cc. Moderate to severe lower urinary tract symptoms (baseline
AUA ≥8, with a median baseline AUA of 7) were reported by
49.4% of patients prior to treatment (Table 2).
Ninety percent of patients were treated with 36.25 Gy in
five 7.25 Gy fractions (Table 1). The median follow-up was
3.9 years. The median pre-treatment PSA of 6.0 ng/ml declined
to a median 3 years post-treatment PSA of 0.3 ng/ml. There were
six biochemical failures, occurring in one low-risk patient, four
intermediate-risk patients, and one high-risk patient. The over-
all 3-year actuarial biochemical relapse free survival was 95.9%.
No patients received ADT at any time during the first 3 years
following SBRT.
Baseline EPIC summary scores are shown in Table 2 and
mean changes in EPIC summary scores from baseline to 3 years
of follow-up are shown in Table 3. The MID value for the uri-
nary domain was 5.5. The EPIC urinary summary score declined
transiently at 1 month post-SBRT (mean change,−7.5) (Table 3;
Figure 1A) and returned to near baseline by 3 months post-SBRT
(mean change from baseline, −1.0) (Table 3; Figure 1A). This
acute decline was both statistically (p< 0.0001) and clinically sig-
nificant. A second late protracted decline occurred between 9
and 18 months (mean change from baseline at 12 months, −4.1)
(Table 3; Figure 1A). The EPIC urinary summary score was close
Table 1 | Patient characteristics at baseline.
Patients
(N =174)
Age Age ≤60 13.80%
60<Age≤70 46.60%
Age >70 39.70%
Race White 55.70%
Black 39.10%
Other 5.20%
Median pre-treatment PSA (ng/mL) 6.0 (1.8–32.5)
Risk groups (D’Amico’s) Low risk 42.00%
Intermediate risk 52.90%
High risk 5.20%
SBRT dose 36.25 Gy 90.20%
35 Gy 9.80%
Table 2 | Pre-treatment quality of life (QOL) scores.
Baseline AUA score % Patients (n=174)
0–7 (mild) 50.6
8–19 (moderate) 44.8
>20 (severe) 4.6
Baseline EPIC-26 summary score Mean SD MID
Urinary domain 89 11.06 5.5
Bowel domain 95 8.81 4.4
to baseline 3 years post-SBRT (mean change from baseline,−2.5)
(Table 3; Figure 1A). The proportion of patients reporting a
clinically significant decline in EPIC urinary domain scores was
34% at 6 months, 40% at 12 months, and 32.8% at 36 months
(Table 4; Figure 2A). The patients reporting a decrease in the
EPIC urinary domain summary score of >2 points was 43.2%
(CI: 33.7%, 54.6%) at 6 months, 51.6% (CI: 43.4%, 59.7%) at
12 months, and 41.8% (CI: 33.3%, 50.6%) at 36 months (Table 5;
Figure 2B).
The MID value for the bowel domain was 4.4. The EPIC bowel
summary score declined transiently at 1 month (mean change,
−9.4) (Table 3; Figure 1B) and experienced a second, more pro-
tracted decline between 9 and 18 months (mean change from base-
line at 12 months,−2.9). Bowel declines at 1 and 12 months were
statistically significant (p< 0.0001); however, only the 1 month
change met the threshold for clinically significant change. The
EPIC bowel summary score were near baseline at 3 years post-
SBRT (mean change from baseline, −2.4) (Table 3; Figure 1B).
The proportion of patients reporting a clinically significant decline
in EPIC bowel domain scores was 30% at 6 months, 32.2% at
12 months, and 21.5% at 36 months (Table 4; Figure 3A). The
patients reporting a decrease in the EPIC bowel domain summary
score of>5 points was 29.6% (CI: 21.9%, 39.3%) at 6 months, 29%
(CI: 22%, 36.8%) at 12 months, and 22.4% (CI: 15.7%, 30.4%) at
36 months (Table 5; Figure 3B).
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Table 3 | Change in EPIC summary domain scores following SBRT for prostate cancer.
Domain 1-month post-RT 3-month post-RT 12-month post-RT 24-month post-RT 36-month post-RT
Mean score Mean score Mean score Mean score Mean score
Change
from
baseline
SD p Change
from
baseline
SD p Change
from
baseline
SD p Change
from
baseline
SD p Change
from
baseline
SD p
Urinary summary −7.5 13.2 <0.0001 −1 10.8 0.200 −4.1 13.6 <0.0001 −1.7 14.9 0.097 −2.5 14.7 0.051
Bowel summary −9.4 18.1 <0.0001 −3.0 12.0 0.0007 −2.9 11.4 <0.0001 −1.6 10.7 0.017 −2.4 13.1 0.004
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FIGURE 1 | EPIC Summary Scores. (A) EPIC urinary summary domain
scores at baseline and following SBRT for prostate cancer. (B) EPIC bowel
summary domain scores at baseline and following SBRT for prostate cancer.
Thresholds for clinically significant changes in scores (one-half SD above and
below the baseline) are marked with dashed lines. EPIC scores range from 0
to 100 with higher values representing a more favorable health-related QOL.
Table 4 | Proportion of patients with clinically significant (> 0.5 SD) declines in EPIC-26 domain scores following SBRT for prostate cancer.
Start 1 month 3 months 6 months 9 months 12 months 18 months 24 months 30 months 36 months
Urinary domain
(decrease >5.5 pts
from baseline)
Median=91.7
Mean=89.3
58.5% 29.2% 34.0% 34.6% 40.0% 37.3% 30.9% 29.9% 32.8%
Bowel domain
(decrease >4.4 pts
from baseline)
Median=100
Mean=94.8
46.8% 24.4% 30.0% 29.4% 32.2% 24.3% 26.8% 29.7% 21.5%
N 174 171 168 162 159 155 142 149 144 134
DISCUSSION
Post-treatment urinary and bowel QOL are important consider-
ations in the management of clinically localized prostate cancer.
Because SBRT is a newer management option for prostate cancer,
longitudinal data reflecting urinary and bowel outcomes have yet
to fully mature (1, 2). Expanded PROs in this area would facilitate
improved clinical trial design and selection of appropriate early
stage interventions.
Consensus is lacking regarding the appropriate PRO end-
points for clinical trials evaluating radiation modalities for
early stage prostate cancer. The EPIC-26 is a commonly
utilized prostate cancer-specific questionnaire (30); however,
limited data are available to guide assessment of meaning-
ful changes in EPIC-26 domain scores. Using a distribution
approach, we found that the urinary domain had a higher
MID value (5.5) than the bowel domain (4.4). Reassuringly,
both MIDs were similar to those recently reported by oth-
ers (28). The availability of these values should aid clini-
cians in utilization of the EPIC-26 for symptom management
decisions.
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FIGURE 2 | Percentage of patients with a clinically significant decline
in EPIC urinary summary domain scores following SBRT for prostate
cancer. (A) Clinically significant decline defined as a one-half SD below
the baseline. (B) Clinically significant decline defined as a deviation in EPIC
urinary domain summary score of >2 points below the baseline per RTOG
0938.
Table 5 | Proportion of patients with decrements that met RTOG 0938 criteria for significant declines in EPIC-26 domain scores following SBRT
for prostate cancer.
Start 1 month 3 months 6 months 9 months 12 months 18 months 24 months 30 months 36 months
Urinary domain
(decrease >2 pts
from baseline)
Median=91.7
Mean=89.3
68.4% 43.5% 43.2%
(33.7–54.6%)
44.7% 51.6%
(43.4–59.7%)
45.8% 42.3%
(34.3–50.7%)
44.4% 41.8%
(33.3–50.6%)
Bowel domain
(decrease >5 pts
from baseline)
Median=100
Mean=94.8
46.8% 23.8% 29.6%
(21.9–39.3%)
30.2% 29.0%
(22.0–36.8%)
24.1% 24.8%
(18.1–32.5%)
29.2% 22.4%
(15.7–30.4%)
N 174 171 168 162 159 155 142 149 144 134
In this study, we show that clinically significant urinary symp-
toms are more common than bowel symptoms over 36 months
following prostate SBRT. Compared to RTOG 0415, the propor-
tion of our patients with 1 year EPIC urinary domain declines
>2 pts was higher (51.6 vs. 40%). However, the proportion of
our patients with 1 year EPIC bowel domain declines >5 pts was
lower (29 vs. 35%). Our patients were treated with 35 or 36.25 Gy
in five fractions, which corresponds to a tumor equivalent dose
in 2-Gy fractions (EQD2) of approximately 85–90 Gy assuming
an α/β ratio of 1.5. Considering this high BED and our inho-
mogeneous treatment plans (31), it is not surprising that the
percentage of our patients experiencing an EPIC urinary domain
score decline was higher than patients treated with low dose
conventionally fractionated intensity-modulated radiation ther-
apy (IMRT) (73.8 Gy) at 1 year after treatment. Unexpectedly, the
percentage of our patients experiencing an EPIC bowel domain
score decline was lower than patients treated on the control arm
of RTOG 0415. We believe that this favorable bowel QOL profile
with SBRT may be secondary to increased accuracy with intrafrac-
tion fiducial tracking and narrowed target volumes, thus sparing
normal rectum from inadvertent irradiation. Which treatment-
related symptom bears the greatest influence on post-treatment
QOL? Utility analyses have shown that bowel symptoms have a
greater negative impact on QOL than urinary symptoms or impo-
tence (32). However, this may not apply for all patients, and shared
decision making may be most appropriate (33).
An important finding of this study is that our prostate SBRT
treatment protocol meets the RTOG 0938 criteria, suggesting that
urinary and bowel QOL is not significantly worse following our
SBRT approach compared with conventionally fractionated IMRT.
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FIGURE 3 | Percentage of patients with a clinically significant decline
in EPIC bowel summary domain scores following SBRT for prostate
cancer. (A) Clinically significant decline defined as a one-half SD below
the baseline. (B) Clinically significant decline defined as a deviation in EPIC
bowel domain summary score of >5 points below the baseline per RTOG
0938.
Based on patient preference for a shorter treatment course, SBRT
utilization is likely to continue to increase as long as post-treatment
QOL is comparable to conventionally fractionated IMRT.
At what time point should PRO endpoint(s) be assessed fol-
lowing prostate SBRT? Due to cost constraints, the timing of
PRO assessments in Phase II trials are commonly limited to
baseline and at one additional key time point that will deter-
mine whether to move the therapy forward to a Phase III trial.
Acute toxicities usually resolve with time, but late toxicities com-
monly persist to cause a greater impact on long-term QOL. The
length of follow-up (at least 36 months) in this cohort permit-
ted us to capture a clinically meaningful difference in urinary
and bowel symptoms, which may not be reflected by evaluating
MID at the time point of 1 year per the existing RTOG pro-
tocol. Evaluation of PROs at a later time point beyond 1 year
may yield more accurate assessment of long-term urinary and
bowel QOL following radiation therapy. Recent evidence sug-
gests that incorporation of web-based QOL survey technology
in clinical trial design may further raise response rates, thus
expanding opportunities to document even longer-term outcomes
(17, 21).
CONCLUSION
Following prostate SBRT, clinically significant urinary symptoms
are more common than bowel symptoms. Our prostate SBRT
treatment protocol meets the RTOG 0938 criteria for moving
forward to a Phase III trial comparison to conventionally frac-
tionated radiation therapy. Notably, between 12 and 36 months,
the proportion of patients reporting a significant decrease in both
EPIC urinary and bowel domain scores declined, suggesting a late
improvement in these symptoms.
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